PMID- 20653781
OWN - NLM
STAT- MEDLINE
DCOM- 20101105
LR  - 20151119
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 57
IP  - 1
DP  - 2010 Jul
TI  - Differential gene expression in classic giant cell tumours of bone: Tenascin C as 
      biological risk factor for local relapses and metastases.
PG  - 59-72
LID - 10.1111/j.1365-2559.2010.03597.x [doi]
AB  - AIMS: To identify candidate prognostic biological markers useful in selecting 
      high-risk patients with classic primary giant cell tumours (GCT). GCT specimens 
      with different behaviour associated with an increased risk of local and/or 
      distant relapses were studied. METHODS AND RESULTS: Screening mRNA microarray 
      analysis followed by real-time polymerase chain reaction and immunohistochemistry 
      on tissue microarray sections was used to validate the prognostic role of 
      differentially expressed genes on a larger series by statistical analysis tests. 
      Global gene expression profiling identified 109 differentially expressed genes 
      according to prognosis. A correlation was found between mRNA levels and clinical 
      outcome identifying Tenascin C (TNC) as the most significant prognostic 
      biological marker. By means of backward Wald logistic regression, TNC 
      overexpression defined an eightfold increased risk for metastasis and fourfold 
      for local recurrence. At the protein level, TNC immunoreactivity resulted in a 
      significant difference in the disease-free survival probability curves, providing 
      a stratification for GCT patients, useful for predicting relapse. CONCLUSIONS: 
      Our study provides important data for the selection of biomarkers with a 
      significant clinical impact and suggests the importance of TNC expression in 
      identifying GCT patients at a higher risk of relapse for closer follow-up and 
      adjuvant medical therapy.
FAU - Pazzaglia, Laura
AU  - Pazzaglia L
AD  - Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, University of 
      Bologna, Bologna, Italy. laura.pazzaglia@ior.it
FAU - Conti, Amalia
AU  - Conti A
FAU - Chiechi, Antonella
AU  - Chiechi A
FAU - Novello, Chiara
AU  - Novello C
FAU - Magagnoli, Giovanna
AU  - Magagnoli G
FAU - Astolfi, Annalisa
AU  - Astolfi A
FAU - Pession, Andrea
AU  - Pession A
FAU - Krenacs, Tibor
AU  - Krenacs T
FAU - Alberghini, Marco
AU  - Alberghini M
FAU - Picci, Piero
AU  - Picci P
FAU - Benassi, Maria Serena
AU  - Benassi MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (Tenascin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Bone Neoplasms/*genetics/metabolism
MH  - Child, Preschool
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression
MH  - Gene Expression Profiling
MH  - Giant Cell Tumor of Bone/*genetics/metabolism/secondary
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/genetics/metabolism
MH  - Oligonucleotide Array Sequence Analysis
MH  - RNA, Messenger/genetics
MH  - RNA, Neoplasm/genetics
MH  - Risk Factors
MH  - Tenascin/*genetics/metabolism
MH  - Young Adult
EDAT- 2010/07/27 06:00
MHDA- 2010/11/06 06:00
CRDT- 2010/07/27 06:00
PHST- 2010/07/27 06:00 [entrez]
PHST- 2010/07/27 06:00 [pubmed]
PHST- 2010/11/06 06:00 [medline]
AID - HIS3597 [pii]
AID - 10.1111/j.1365-2559.2010.03597.x [doi]
PST - ppublish
SO  - Histopathology. 2010 Jul;57(1):59-72. doi: 10.1111/j.1365-2559.2010.03597.x.